DexCom (DXCM) director Bridgette Heller sells 1,012 shares in planned trade

Rhea-AI Filing Summary

DexCom Inc. director Bridgette P. Heller reported an open-market sale of 1,012 shares of Common Stock on August 12, 2026 at $88.29 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025. After this transaction, she directly holds 29,570 shares, including 5,575 unvested restricted stock units that were granted on May 28, 2026 and will vest on the earlier of the one-year anniversary of the grant date or DexCom’s 2027 Annual Meeting of Stockholders.

Insider Trade Summary 10b5-1

Net Seller: 1,012 shares

Net Sell 1 txn

Insider Heller Bridgette P

Role Director

Sold 1,012 shs ($89K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,012	$88.29	$89K

Holdings After Transaction: Common Stock — 29,570 shares (Direct)

Footnotes (2)

1. F1. On August 14, 2025, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan.
2. F2. Included in this number are 5,575 unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Key Figures

Shares sold: 1,012 shares Sale price per share: $88.29 per share Shares held after transaction: 29,570 shares +1 more

4 metrics

Shares sold 1,012 shares Common Stock sold by director on August 12, 2026

Sale price per share $88.29 per share Price for the 1,012 shares of Common Stock sold

Shares held after transaction 29,570 shares Direct holdings reported for Ms. Heller following the sale

Unvested RSUs included in holdings 5,575 restricted stock units Granted May 28, 2026; vest by one-year anniversary or 2027 Annual Meeting

Key Terms

Rule 10b5-1 Plan, restricted stock units, Annual Meeting of Stockholders

3 terms

Rule 10b5-1 Plan regulatory

"This 10b5-1 Plan allows the orderly disposition of shares"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"Included in this number are 5,575 unvested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Annual Meeting of Stockholders regulatory

"or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"

FAQ

What insider transaction did DexCom (DXCM) disclose for Bridgette P. Heller?

DexCom reported that director Bridgette P. Heller sold 1,012 shares of DexCom Common Stock on August 12, 2026. The transaction was classified as a sale in the open market or private transaction at a reported price of $88.29 per share.

Was the August 12, 2026 DexCom (DXCM) insider sale under a Rule 10b5-1 plan?

Yes. The filing states Ms. Heller adopted a Rule 10b5-1 Plan on August 14, 2025. It further explains that the 1,012 shares sold on August 12, 2026 were sold pursuant to this 10b5-1 Plan, which allows orderly disposition of her shares.

How many DexCom (DXCM) shares does Bridgette P. Heller hold after the reported sale?

Following the transaction, Ms. Heller directly holds 29,570 DexCom shares. This total includes 5,575 unvested restricted stock units that were granted on May 28, 2026 and are scheduled to vest by the earlier of one year from grant or the 2027 Annual Meeting.

What price did DexCom (DXCM) director Bridgette P. Heller receive for the shares sold?

The reported transaction price was $88.29 per share for the 1,012 DexCom Common Stock shares sold on August 12, 2026. The filing labels this as a per-share price for a sale in the open market or a private transaction.

What are the terms of the unvested DexCom (DXCM) restricted stock units held by Bridgette P. Heller?

Ms. Heller’s post-transaction holdings include 5,575 unvested restricted stock units. These RSUs were granted on May 28, 2026 and will vest on the earlier of the one-year anniversary of the grant date or DexCom’s 2027 Annual Meeting of Stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 04:04 PM Accepted by SEC EDGAR 08/13/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heller Bridgette P

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		S		1,012(1)	D	$88.29	29,570(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 14, 2025, Ms. Heller adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Ms. Heller. The shares set forth above were sold pursuant to the 10b5-1 Plan.

2. Included in this number are 5,575 unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Bridgette P. Heller	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)